Expiring patents can be a catalyst for M&A in the life sciences industry as pharmaceutical and biotechnology companies seek to maintain revenue streams and competitive advantages. In this edition of Beyond the Deal, our...more
4/14/2025
/ Acquisitions ,
Artificial Intelligence ,
Biosimilars ,
Biotechnology ,
Competition ,
Generic Drugs ,
Life Sciences ,
Mergers ,
Patent Expiration ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prescription Drugs
On June 9, 2015, the U.S. Court of Appeals for the D.C. Circuit, in its ruling in Pharm. Research & Mfrs. of Am. v. FTC, upheld the FTC's expansion of HSR reporting requirements for pharmaceutical companies, and solidified...more